Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions

Area of Science:

• Hepatology
• Genetics
• Pulmonology

Background:

• Alpha-1 antitrypsin deficiency (A1ATD) is the primary genetic cause of liver disease in children.
• It is a protein-folding disorder characterized by the accumulation of misfolded alpha-1 antitrypsin Z (ATZ) protein in hepatocytes.
• This aggregation leads to endoplasmic reticulum stress, inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma, and also predisposes adults to panlobular emphysema.

Purpose of the Study:

• To review the liver disease associated with alpha-1 antitrypsin deficiency (A1ATD).
• To cover the pathogenesis, epidemiology, diagnostic methods, and emerging therapeutic strategies for A1ATD-related liver disease.

Main Methods:

• Literature review of studies on alpha-1 antitrypsin deficiency and associated liver disease.
• Analysis of current and emerging therapeutic targets and strategies.
• Synthesis of information on disease mechanisms, diagnosis, and treatment.

Main Results:

• Current therapeutic strategies focus on intracellular pathways to mitigate the toxic effects of misfolded ATZ protein.
• Approaches include enhancing ATZ clearance from the endoplasmic reticulum (ER), promoting its degradation, and inhibiting protein aggregation.
• Orthotopic liver transplantation is the only currently approved curative therapy for A1ATD-associated liver disease.

Conclusions:

• Significant advancements have been made in developing small molecule therapies.
• These novel therapies hold promise for preserving native liver function and preventing hepatotoxicity in A1ATD patients.
• A1ATD represents a critical area for therapeutic innovation in genetic liver disease.